glp-1/gip treatment Science Behind GLP 1 GIP and Glucagon Receptor Agonists for Obesity Research | News & Announcements Get Microdosing GLP-1 / GIP

(2004) Estrogen Regulation of Growth Hormone Action Rosa Sirianni, et al

10.1038/srep04681 Sci

PubMed Central Petty AJ, Floyd L, Henderson C, Nicholas MW

The Truth Emerges On July 29, 2025, Novo issued a press release and held a conference call lowering its sales and profit outlook for 2025, citing "lowered growth expectations for the second half of 2025" for both Wegovy and Ozempic due to "the persistent use of compounded GLP-1s, slower-than-expected market expansion and competition." Management also noted that despite the expiry of the FDA grace period for mass compounding on May 22, 2025, company research showed that unsafe and unlawful mass compounding continued

For the bigger picture, read how supervised peptide therapy at Perfect B in Doral is structured and how it supports safe, monitored use of peptides